Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 FY- Text added to 2023 FY
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
adult, Altman, AML, antagonize, antidilutive, Antonio, Artificial, ASCO, azacytidine, Baylor, Biochemistry, broken, capivasertib, carboplatin, CBAY, CDK, cero, Christian, covalent, Dinner, disaggregated, endocrine, epidermal, erroneously, FA, faster, fibroblast, fourteen, HHS, ISO, Jennifer, Jessica, Leukemia, Lurie, Myeloid, noncurrent, NYSE, OTC, overexpression, polymorph, preoperative, proliferative, reclassifying, recovery, refractory, relapse, remodeling, Robert, ROU, run, Schema, seventeen, Shira, Society, staining, Symposium, synergistically, tabular, TCRX, threat, TNBC, tornado, trimer, triplet, Tscan, umbrella, unchanged, unconfirmed, underway, unlisted, upward, venetoclax, Wainwright, Xencor, XNCR, ZF, ZFA
Valuein 2022 FY filing- Value in 2023 FY filing
Original filings
Filing view